MDT at a glance
Medtronic (MDT, SEC CIK 1613103) filed its latest 10-K annual report on June 18, 2026, a 10-Q quarterly report on September 3, 2026, an 8-K current report on September 17, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended April 24, 2026 (FY2026), Medtronic (MDT) reported revenue of $36.4 billion (up 8.4% from FY2025) and net income of $4.8 billion. Diluted EPS was $3.73.
- As of June 30, 2026, 61 institutional investment managers tracked by SignalX reported holding Medtronic (MDT) shares worth $40.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by KIIL HARRY SKIP on September 16, 2026 of 1,483 shares at $93.65 per share.
- In the last 90 days, MDT insiders reported 0 open-market purchases ($0) and 1 open-market sale ($139K) on Form 4, a net sale of $139K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $36.4B
- +8.4% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$139K
- 13F holders
- 61 funds
- $40.0B · +2 vs prior quarter
- Latest 8-K
- Sep 17, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Apr 24, 2026
Risk Factors
- EU Medical Device Regulation (EU MDR) implementation extended to 2028, imposing additional pre- and post-market requirements and severe penalties for non-compliance
- Russia-Ukraine conflict causing supply chain risks from materials like palladium and neon; Russia and Belarus sanctions disrupt regional business activities
- Sole-source sterilization facilities with limited capacity create risk of manufacturing delays or lost sales if facilities are damaged or closed
- Competition from pharmaceutical companies producing GLP-1s and emerging AI-enabled digital health tools may disrupt market share and product adoption
- Ongoing U.S. tax litigation over income allocation to Puerto Rico manufacturing site with appellate remand in 2025 could materially impact financial condition
Business Overview
- Core business model: Global healthcare technology company developing, manufacturing, and selling device-based medical therapies and services across Cardiovascular, Neuroscience, and Medical Surgical segments
- New strategic emphasis: Separation and IPO of Diabetes Business into independent public company MiniMed Group in March 2026
- Strategic shift: Focus on AI, data analytics, and automation to tailor therapies and enable remote monitoring care delivery
- Notable quantitative metric: Over 95,000 full-time employees globally, with 43% based in U.S. or Puerto Rico; achieved 100% U.S. pay equity by gender and ethnicity
- Unique fact in 2026 filing: Diabetes segment is no longer reportable post-MiniMed IPO, affecting segment comparability in future financial metrics
Management Discussion & Analysis
- Revenue $36.4B, up 8.4% YoY from $33.5B driven by growth across Cardiovascular (+12% to $14.0B), Neuroscience (+4% to $10.3B), Medical Surgical (+5% to $8.8B), and Diabetes (+13% to $3.1B)
- Operating margin info not explicitly given; cost of products sold margin increased with COGS $12.7B vs $11.6B, SG&A increased $11.8B vs $10.8B, R&D increased $2.9B vs $2.7B; effective tax rate 21.2% vs 16.6%, non-GAAP nominal tax 17.3% vs 16.7%
- Best performing segment: Cardiovascular, net sales $13.98B, +12% YoY; Worst performing segment by growth: Specialty Therapies, +2% to $3.0B
- Free cash flow $5.43B vs $5.19B; capital allocation included share repurchases 10M shares ($932.5M avg price), dividends (not quantified), $1.9B capex; $3.3B net increase in debt issuance/repayments, IPO proceeds $538M from MiniMed
- Forward outlook risks: $250M estimated tariffs in FY27, geopolitical risks (Russia-Ukraine, Middle East conflicts), impact of Diabetes separation, regulatory/commercial challenges; growth expected in cardiovascular device adoption and new product launches, Neuroscience AI-assisted surgery growth, Medical Surgical robotics expansion
AI summary of the MDT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 31, 2026
Management Discussion & Analysis
- Revenue $9.756B, up 14% YoY from $8.578B, including approximately $570M from the extra fiscal week
- Electrophysiology Therapies best-performing division, sales $2.218B, up 30% YoY
- Neuromodulation worst-performing division, sales $539M, up 5% YoY
- Operating cash flow $1.793B vs $1.088B YoY; free cash flow $1.290B vs $584M
- Headwinds: tariffs, pricing pressure, reimbursement challenges, currency fluctuations, supply-chain risks, and Diabetes separation costs
AI summary of the MDT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Exchange offer targets up to 225,361,295 newly issued MiniMed shares for Medtronic ordinary shares
- Potential oversubscription acceptance capped at an additional 2% of outstanding Medtronic shares
Item 2.02: Results of Operations and Financial Condition
- Medtronic announced first-quarter fiscal 2027 financial results on September 1, 2026
- Detailed results, guidance, and management commentary are in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q1 FY27 revenue $9.756B, up 13.7% organic, benefiting approximately $570M from the extra fiscal week
- Non-GAAP diluted EPS $1.45, up 15.1%; operating margin 23.7% versus 23.6% prior year
Item 2.02: Results of Operations and Financial Condition
- FY2026 and fourth-quarter financial results announced on June 3, 2026
- Exhibit 99.1 contains the detailed earnings release for investor review
AI summaries of MDT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MDT
Don't miss the next MDT filing
- Alerts as it files. A push when MDT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MDT, by share count.
- Ask anything. An AI agent that reads every MDT filing and answers with sources.
MDT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| KIIL HARRY SKIP | Sell | Sep 16, 2026 | 1,483 | $93.65 |
| Blomquist Denise L. | G | Sep 15, 2026 | 600 | - |
| Marinaro Michael | F | Aug 20, 2026 | 1,084 | $92.30 |
| Blomquist Denise L. | A | Aug 3, 2026 | 2,337 | - |
| Pieton Thierry | A | Aug 3, 2026 | 11,537 | - |
| Blomquist Denise L. | A | Aug 3, 2026 | 2,337 | - |
| Thompson Kweli | A | Aug 3, 2026 | 17,306 | - |
| Thompson Kweli | A | Aug 3, 2026 | 49,167 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | $32.4B | $33.5B | $36.4B |
| Operating Income | - | $6.0B | $6.5B |
| Net Income | $3.7B | $4.7B | $4.8B |
| Op. Margin | - | 17.8% | 17.8% |
| Net Margin | 11.4% | 13.9% | 13.2% |
| Balance Sheet | |||
| Total Assets | - | $91.7B | $93.0B |
| Equity | $50.2B | $48.0B | $49.5B |
| ROE | 7.3% | 9.7% | 9.7% |
| Per Share | |||
| EPS | $2.76 | $3.61 | $3.73 |
| Cash Flow | |||
| Operating CF | - | $7.0B | $7.3B |
| CapEx | - | $1.9B | $1.9B |
Source: XBRL data in Medtronic (MDT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MDT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 61 | $40.04B |
| Q1 2026 | 59 | $44.43B |
| Q4 2025 | 58 | $51.62B |
| Q3 2025 | 58 | $57.21B |
| Q2 2025 | 62 | $48.01B |
| Q1 2025 | 56 | $36.97B |
| Q4 2024 | 52 | $24.91B |
| Q3 2024 | 50 | $15.94B |
- Citadel Advisors LLC+4.39M (+447%)
- D.E. Shaw & Co+3.50M (+391%)
- Goldman Sachs Group+3.41M (+61%)
- Franklin Resources+3.38M (+24%)
- Two Sigma Investments+2.64M (+435%)
- JPMorgan Chase & Co−23.19M (-45%)
- Bank of America Corp−4.69M (-18%)
- Truist Financial−1.56M (-56%)
- Morgan Stanley−1.27M (-6%)
- BNY Mellon−807.6K (-5%)
- COHEN & STEERS, INC.−1.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 456 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MDT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 10-Q | Sep 3, 2026 | Jul 31, 2026 | Analysis | |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 10-K | Jun 18, 2026 | Apr 24, 2026 | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
MDT SEC filings: frequently asked questions
Are MDT insiders buying or selling?
In the last 90 days, Medtronic (MDT) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $138,883 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MDT stock?
As of June 30, 2026, the largest Medtronic (MDT) holders among the 13F filers tracked by SignalX were BlackRock ($8.9 billion), Vanguard Capital Management LLC ($6.6 billion), State Street Corp ($5.0 billion), Vanguard Portfolio Management LLC ($2.7 billion), JPMorgan Chase & Co ($2.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MDT's revenue in fiscal year 2026?
For the fiscal year ended April 24, 2026 (FY2026), Medtronic (MDT) reported revenue of $36.4 billion (up 8.4% from FY2025) and net income of $4.8 billion. Diluted EPS was $3.73. The figures come from the XBRL data in the 10-K.
What are the main risks in MDT's latest 10-K?
In the 10-K filed June 18, 2026, Medtronic (MDT) flagged: EU Medical Device Regulation (EU MDR) implementation extended to 2028, imposing additional pre- and post-market requirements and severe penalties for non-compliance. Russia-Ukraine conflict causing supply chain risks from materials like palladium and neon; Russia and Belarus sanctions disrupt regional business activities. (AI summary of the Risk Factors section.)
What did MDT report in its latest 8-K?
Medtronic (MDT) filed an 8-K on September 17, 2026 reporting Item 8.01 (Other Events). Exchange offer targets up to 225,361,295 newly issued MiniMed shares for Medtronic ordinary shares.
What are the latest MDT SEC filings?
Medtronic (MDT) filed its latest 10-K annual report on June 18, 2026, a 10-Q quarterly report on September 3, 2026, an 8-K current report on September 17, 2026 and a Form 4 insider filing on September 17, 2026.
What is MDT's SEC CIK number?
Medtronic (MDT)'s SEC Central Index Key (CIK) is 1613103. EDGAR lists every MDT filing under that number.
Ask anything about MDT
The research agent reads MDT's filings, financials, insider trades and 13F holders, then answers with sources.